<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330288</url>
  </required_header>
  <id_info>
    <org_study_id>19649</org_study_id>
    <nct_id>NCT03330288</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment</brief_title>
  <official_title>Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a TheraflexÂ® Treatment to Evaluate Changes in Pain, Functions in Daily Living, and Quality of Life for an Observation Period up to 64 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate how a long-term treatment with Theraflex during
      64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily
      living, the quality of life and patient satisfaction with treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other information that is planned for evaluation in this study includes consumption of
      Theraflex, intake of analgesics for joint pain relief and description of basic patient
      characteristics such as age, weight and body mass index and others.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">January 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in quality of life assessed by Knee injury and Osteoarthritis Outcome Score (KOOS) in patients with knee OA</measure>
    <time_frame>Up to 64 weeks</time_frame>
    <description>Changes in pain, other symptoms, functions and knee related quality of life assessment will all be collected by KOOS questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in quality of life assessed by Hip injury and Osteoarthritis Outcome Score (HOOS) in patients with hip OA</measure>
    <time_frame>Up to 64 weeks</time_frame>
    <description>Changes in pain, others symptoms, functions and hip related quality of life assessment will all be collected by HOOS questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug utilization of Theraflex therapy</measure>
    <time_frame>Up to 64 weeks</time_frame>
    <description>as reported by the patient to their physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction measured with a Likert response scale</measure>
    <time_frame>Up to 64 weeks</time_frame>
    <description>measured with a Likert response scale (from 1-very dissatisfied to 5 - very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painkiller usage - type</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painkiller usage - length</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painkiller usage - frequency</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other medical/physical therapy usage-type</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other medical/physical therapy usage-frequency</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other medical/physical therapy usage-length</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Patients with Hip OA stage I to III</arm_group_label>
    <description>Male and female patients from 45 to 75 of age with Hip osteoarthritis stage I to III</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Knee OA stage I to III</arm_group_label>
    <description>Male and female patients from 45 to 75 of age with knee osteoarthritis stage I to III</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theraflex, BAY 874017</intervention_name>
    <description>The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day</description>
    <arm_group_label>Patients with Hip OA stage I to III</arm_group_label>
    <arm_group_label>Patients with Knee OA stage I to III</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who will be made aware about the study either by the treating physician OR by a
        pharmacist where a patient is purchasing Theraflex
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 45 to 75 years with Hip or Knee OA stage I to III

          -  Patient started current treatment with Theraflex not more than 2 weeks prior to
             inclusion into the study

          -  Personally signed and dated informed consent

        Exclusion Criteria:

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice

          -  Patients with Hip or Knee OA stage 0 or stage IV

          -  Patients who have both Hip and Knee OA and OA of any other location.

          -  Contraindications for use of Theraflex in accordance with approved label(known
             hypersensitivity, severe chronic renal failure)

          -  Females who are pregnant or breastfeeding

          -  Patients who completed a treatment with Theraflex or another combination of Gl+ Ch
             less than 5 months before start of the current treatment

          -  Patients who completed intra-articular corticosteroids treatment in the last 3 months
             to exclusion criteria

          -  Patients who completed hyaluronic injections of the lower limbs in the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>+1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Many locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

